

Leading Driver In The Phenobarbital Market 2025: Growth Of The Phenobarbital Market Due To Rising Seizure Cases Globally

The Business Research Company's Phenobarbital Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- A key focus of the report is the robust growth of the



phenobarbital market in recent years. The market valuation is expected to surge from \$1.47 billion in 2024 to \$1.55 billion in 2025, reflecting a compound annual growth rate CAGR of 5.4%. This growth is underpinned by several factors, including the widespread use of phenobarbital in epilepsy management, a rise in the prevalence of epilepsy and seizure disorders, government



The Business Research
Company's Phenobarbital
Global Market Report 2025 –
Market Size, Trends, And
Global Forecast 2025-2034"

The Business Research
Company

supply programs, an upswing in demand in veterinary applications, and efforts toward widespread health coverage.

What Is The Projected Future Growth Of The <u>Phenobarbital</u> Market Size?

Looking forward, the phenobarbital market is set to witness substantial expansion. The market cap is anticipated to reach \$1.91 billion in 2029, with a CAGR of 5.2%. The market's growth in the forecast period is

attributed to factors such as the proliferation of generic drug manufacturing, increasing focus on neurological disease management, the advancement of digital supply chains and e-pharmacy systems, regulatory changes favoring generic use, and stability in regulatory pathways for generics. The market is also expected to be influenced by major trends like development of easy-to-administer delivery forms, innovative R&D efforts, extended-release formulations, enhanced drug delivery systems,

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Are The Key Drivers Propelling The Growth Of The Phenobarbital Market? Epilepsy, a neurological disorder characterized by recurrent unprovoked seizures resulting from abnormal electrical activity in the brain, is becoming increasingly prevalent due to enhanced awareness leading to more people recognizing symptoms and seeking medical diagnosis. Phenobarbital, an anticonvulsant medication that works by slowing down the activity of the brain's neurons, is particularly effective in preventing and controlling seizures. The increase in epilepsy cases is expected to drive the phenobarbital market forward.

What Key Player Strategies Are Driving The Phenobarbital Market?

The report identifies the major companies operating in the phenobarbital market. These include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, H. Lundbeck A/S, Sandoz Group AG, Yashiro Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Par Pharmaceutical Inc., Shandong Xinhua Pharmaceutical Co. Ltd., Manus Aktteva Biopharma LLP, JPN Pharma Pvt. Ltd., Alkaloida Chemical Company Zrt., and Harman Finochem Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

What Are The Emerging Trends In The Phenobarbital Market?

Increasingly, companies in the phenobarbital market are striving to innovate and develop effective solutions such as phenobarbital sodium, which enhances the safety and effectiveness of treatments. For example, in January 2023, India-based Sun Pharmaceutical Industries Ltd launched SEZABY phenobarbital sodium in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates.

How Is The Phenobarbital Market Segmented?

The phenobarbital market covered in this report is broken down by indication, dosage forms, distribution channels, applications, and by end users. Additionally, epilepsy is segmented into focal partial seizures, generalized tonic-clonic seizures, status epilepticus, refractory epilepsy, and idiopathic epilepsy, while neonatal seizures are broken down further into subsegments.

What Are The Regional Insights In The Phenobarbital Market?

In 2024, North America was found to be the largest region in the phenobarbital market, with Asia-Pacific predicted to be the fastest-growing region during the forecast period. The regions analyzed in the phenobarbital market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company: Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Artificial Intelligence (AI) In Drug Discovery Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Atherosclerosis Drugs Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company/ YouTube: https://www.youtube.com/channel/UC24 fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/823646941

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.		